Wegovy Medicare Advantage Coverage: What's Covered in 2026 and How to Lower Your Cost

How Medicare Advantage Plans Cover Wegovy in 2026

Most Medicare Advantage (MA) plans with Part D prescription drug benefits now include Wegovy on their formularies, though placement varies between preferred specialty tier and non-preferred specialty tier. This represents a significant shift from 2023, when the majority of Medicare plans explicitly excluded anti-obesity medications from coverage under the long-standing Medicare Part D statutory exclusion for weight-loss drugs.

The change traces back to the anti-obesity medication provisions embedded in the Inflation Reduction Act's broader drug-pricing framework and subsequent CMS guidance issued in late 2024. CMS clarified that semaglutide 2.4 mg (Wegovy) could be covered when prescribed for its FDA-approved indications, which include chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. The SELECT cardiovascular outcome trial data also supported coverage for cardiovascular risk reduction, a secondary FDA-approved indication granted in March 2024 [1].

Not every MA plan covers Wegovy identically. Plans offered by UnitedHealthcare, Humana, Aetna, and CVS/SilverScript have published formularies for 2026 that include Wegovy, but tier placement and cost-sharing structures differ. You need to check your specific plan's formulary document or call the number on the back of your member card.

Prior Authorization Requirements for Wegovy Under Medicare Advantage

Every major Medicare Advantage insurer requires prior authorization before dispensing Wegovy. The process typically takes 3 to 10 business days and requires your prescribing clinician to submit documentation showing you meet specific clinical criteria.

Standard prior authorization criteria across most MA plans include: a documented BMI of 30 or greater (or 27 or greater with a qualifying comorbidity), failure of lifestyle modifications alone for at least 6 months, no active medullary thyroid carcinoma or MEN2 syndrome, and no current pregnancy or planned pregnancy within 2 months. Some plans additionally require documentation that the patient has attempted at least one other pharmacotherapy for weight management, though this "step therapy" requirement has become less common in 2026 formularies [2].

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that clinicians initiate GLP-1 receptor agonist therapy without requiring failure of older agents like orlistat or phentermine-topiramate, calling step therapy requirements "not evidence-based." If your plan denies coverage based on step therapy, your physician can file a formulary exception citing this guideline.

Denials happen. Roughly 20% to 30% of initial prior authorization requests for GLP-1 receptor agonists are denied according to pharmacy benefit manager data. Appeals succeed in approximately 40% to 60% of cases when supported by adequate clinical documentation.

What You'll Actually Pay Out of Pocket

Your monthly cost for Wegovy under Medicare Advantage depends on three variables: formulary tier placement, your plan's cost-sharing structure for that tier, and whether you've met your deductible and hit the catastrophic coverage phase.

On most 2026 MA-PD plans, Wegovy sits on Tier 5 (specialty tier), which carries coinsurance of 25% to 33% rather than a flat copay. At Wegovy's wholesale acquisition cost of approximately $1,349 per month, that translates to $337 to $445 in monthly coinsurance before any additional savings programs apply.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective in 2025, changes this math substantially. Once your total Part D out-of-pocket spending hits $2 to 000 in a calendar year, you pay $0 for covered drugs for the remainder of that year. For a patient taking Wegovy year-round, this cap is typically reached within the first 4 to 6 months, after which monthly costs drop to zero [3].

Some MA plans with enhanced benefits have placed Wegovy on Tier 3 (preferred brand) with flat copays of $47 to $95 per month. These plans tend to carry higher monthly premiums but may offer better total value for patients who know they'll use Wegovy continuously.

The SELECT Trial: Why Cardiovascular Coverage Changed Everything

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or greater, but without diabetes. Over a mean follow-up of 39.8 months, semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% compared to placebo (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001) [4].

This trial changed the coverage conversation entirely. CMS and Medicare Advantage insurers could no longer classify Wegovy solely as a "weight-loss drug" when it carried an FDA-approved cardiovascular indication with hard-outcome data. Dr. A. Michael Lincoff, the trial's principal investigator at the Cleveland Clinic, stated in the New England Journal of Medicine publication: "These findings establish that treatment of obesity with semaglutide reduces major adverse cardiovascular events independent of baseline weight or the amount of weight loss achieved" [4].

For Medicare beneficiaries, this means that if your physician prescribes Wegovy specifically for cardiovascular risk reduction (rather than weight management alone), the coverage pathway may be more straightforward. Several MA plans have created separate prior authorization pathways for the cardiovascular indication that bypass the step therapy and lifestyle modification documentation requirements applied to the obesity indication.

How to Get Wegovy at the Lowest Possible Cost

Multiple strategies exist for reducing your out-of-pocket Wegovy expense, and they can be combined.

Novo Nordisk Patient Assistance Program (PAP). Medicare beneficiaries with annual household income below 400% of the federal poverty level ($62,400 for an individual in 2026) may qualify for Wegovy at no cost through Novo Nordisk's patient assistance program. This program provides the medication directly at $0 for qualifying patients. Application requires proof of income and Medicare enrollment.

Medicare Part D Extra Help (Low-Income Subsidy). Beneficiaries who qualify for Extra Help pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs in 2026. Wegovy, as a brand-name product, would fall under the $11.20 copay for qualified individuals. Income thresholds for Extra Help are approximately $22,590 for individuals and $30,660 for couples [5].

Plan shopping during Annual Enrollment Period. The Medicare Plan Finder tool at medicare.gov allows you to enter your specific medications and compare total annual costs across all available MA-PD plans in your zip code. The difference between the cheapest and most expensive plan for a Wegovy user can exceed $3,000 annually.

Specialty pharmacy programs. Some MA plans contract with specialty pharmacies that offer lower cost-sharing for GLP-1 medications when dispensed through their preferred network. Ask your plan whether a specialty pharmacy option carries lower coinsurance than retail.

The Novo Nordisk manufacturer savings card (the "WeGoTogether" card) is not valid for Medicare beneficiaries. Federal anti-kickback statutes prohibit manufacturer copay cards for patients covered by federal healthcare programs including Medicare and Medicaid [6].

Wegovy vs. Compounded Semaglutide: What Medicare Covers

Compounded semaglutide, available from 503B outsourcing facilities and compounding pharmacies at an average cost of $199 per month, is not covered by Medicare Advantage plans. Medicare Part D covers only FDA-approved medications from the manufacturer, not compounded versions.

The FDA has stated that compounded semaglutide products have not undergone the same safety and efficacy testing as Wegovy and Ozempic. However, for Medicare beneficiaries who cannot obtain coverage for brand-name Wegovy, compounded semaglutide represents a cash-pay alternative at roughly 85% lower cost.

Key differences to understand: compounded semaglutide may use the salt form (semaglutide sodium) rather than the base form used in Wegovy, dosing standardization varies between compounding pharmacies, and no cardiovascular outcome data exist for compounded formulations specifically. The STEP trials and SELECT trial enrolled patients exclusively on Novo Nordisk's branded product [7].

If you choose the compounded route, verify that your pharmacy is an FDA-registered 503B outsourcing facility subject to current good manufacturing practice (cGMP) requirements, not a 503A pharmacy compounding individual prescriptions with less regulatory oversight.

Step-by-Step: Getting Wegovy Approved Through Your MA Plan

The approval process follows a predictable sequence. Here is what to expect.

Step 1: Confirm formulary coverage. Log into your MA plan's member portal or call member services. Ask specifically whether Wegovy (semaglutide 2.4 mg injection) appears on the 2026 formulary and on which tier. Request the prior authorization criteria document.

Step 2: Clinical documentation. Your prescribing clinician needs to document: current BMI (measured in office), weight-related comorbidities, duration of obesity, prior lifestyle modification attempts (diet, exercise, behavioral counseling), and any prior pharmacotherapy trials. The more thorough the documentation, the higher the first-pass approval rate.

Step 3: Prior authorization submission. Your clinician's office submits the PA request electronically through the plan's pharmacy benefit manager (CVS Caremark, Express Scripts, OptumRx, or others). Standard processing takes 72 hours. Urgent requests can be processed in 24 hours if your physician certifies medical necessity for expedited review.

Step 4: If denied, appeal. First-level appeals are reviewed by a physician at the pharmacy benefit manager. Include the Endocrine Society guideline recommendation [8], your specific cardiovascular risk factors, and any relevant specialist consultation notes. Second-level appeals go to an independent review entity.

Step 5: External review. If the plan upholds its denial after internal appeal, Medicare beneficiaries have the right to request an independent external review through the Medicare Appeals Council. Success rates at this level exceed 50% for anti-obesity medications with adequate documentation.

Clinical Eligibility: Who Qualifies and Who Doesn't

Wegovy's FDA-approved indication covers adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related comorbidity. Medicare Advantage plans follow these same criteria but may add plan-specific requirements.

Qualifying comorbidities recognized by most MA plans include: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, non-alcoholic fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease, or MASLD), and osteoarthritis of weight-bearing joints.

Contraindications that will result in coverage denial include: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, current pancreatitis, and hypersensitivity to semaglutide. The FDA prescribing information also carries warnings regarding gallbladder disease, acute kidney injury, and diabetic retinopathy complications in patients with existing retinal disease [9].

A practical note on BMI documentation: if your BMI currently falls below 27, you will not qualify for coverage regardless of prior weight history. Some patients who lost weight on other interventions but regained may need to have their current weight documented at the time of the prior authorization request.

The 2025-2026 Policy Shift: How Coverage Expanded

Before 2024, Medicare Part D explicitly excluded coverage for drugs used for "anorexia, weight loss, or weight gain" under Section 1860D-2(e)(2)(A) of the Social Security Act. This exclusion dated to 2003 and was enacted when the only available obesity medications had modest efficacy and significant safety concerns.

The Treat and Reduce Obesity Act, which had been introduced repeatedly since 2012, finally gained momentum after the SELECT trial data. Provisions addressing Medicare coverage of anti-obesity medications were incorporated into broader healthcare legislation signed in late 2024. CMS published implementing guidance in early 2025 that allowed Medicare Part D plans to cover FDA-approved anti-obesity medications beginning with the 2025 plan year, with full formulary integration expected by 2026 [10].

The Congressional Budget Office estimated that covering anti-obesity medications under Medicare would cost approximately $35 billion over 10 years but would be partially offset by reduced spending on cardiovascular events, joint replacements, diabetes management, and other obesity-related conditions. A 2023 analysis published in JAMA Network Open estimated that if 10% of eligible Medicare beneficiaries used GLP-1 receptor agonists for obesity, Medicare spending on these drugs alone would reach $13.6 billion annually [11].

Not all MA plans implemented coverage at the same pace. Plans with larger pharmacy budgets (typically those charging higher premiums) added Wegovy in the 2025 plan year. Others waited for 2026, and a small number of plans continue to limit coverage to the cardiovascular indication only.

What Happens If Your Plan Still Denies Coverage

Some Medicare Advantage plans restrict Wegovy coverage to the cardiovascular indication (SELECT-eligible patients with established CVD) and deny it for weight management alone. If you face this situation, several options remain.

Request a formulary exception based on medical necessity. Under Medicare Part D regulations, plans must grant exceptions when a prescriber demonstrates that the requested drug is medically necessary for the enrollee and that formulary alternatives would not be as effective or would cause adverse effects. Your physician can argue that Wegovy's 15% mean weight loss [12] significantly exceeds alternatives like orlistat (2.5% to 3% placebo-subtracted) and that the cardiovascular risk reduction benefit applies to your patient profile.

Consider switching plans during the Annual Enrollment Period (October 15 through December 7) or during a Special Enrollment Period if you qualify. The difference between plans regarding Wegovy coverage is substantial, and a plan switch may save thousands annually.

For patients with established cardiovascular disease, ask your cardiologist to prescribe Wegovy under the MACE-reduction indication (FDA-approved March 2024) rather than the weight management indication. This often triggers a different, more favorable prior authorization pathway.

The American Heart Association's 2024 obesity management guideline states: "For patients with established atherosclerotic cardiovascular disease and overweight or obesity, semaglutide 2.4 mg weekly should be considered as a first-line pharmacotherapy given demonstrated reduction in major adverse cardiovascular events" [13].